On May 10, 2017, Amgen filed a complaint in the District of Delaware asserting that, under section 35 U.S.C. § 271(e)(2)(C)(i) of the Biologics Price Competition and Innovation Act (“BPCIA”), Coherus infringed Amgen’s U.S....more
5/18/2017
/ aBLA ,
Amgen ,
Biologics ,
Biosimilars ,
BPCIA ,
Civil Conspiracy ,
Food and Drug Administration (FDA) ,
Misappropriation ,
Patent Dance ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Trade Secrets
On March 2, 2017, the United States District Court for the District of Massachusetts issued an order in Janssen v. Celltrion explaining that an accused patent infringer’s failure to fully engage in the Biologics Price...more
3/30/2017
/ Biosimilars ,
BPCIA ,
Good Faith ,
Information Sharing ,
Lost Profits ,
Patent Dance ,
Patent Infringement ,
Patent Royalties ,
Patents ,
Pharmaceutical Patents ,
Remedies
On Monday, January 9, 2017, the U.S. Supreme Court denied, without comment, Mylan Pharmaceuticals’ petition for certiorari to reverse an opinion by the Court of Appeals for the Federal Circuit, which affirmed a broad scope of...more
On Friday, March 18, the Court of Appeals for the Federal Circuit affirmed two District of Delaware rulings that non-resident defendant generic ANDA filer, Mylan, is subject to personal jurisdiction in two Hatch-Waxman suits...more